Here's a classic biotech story: a company announces promising clinical trial results, the stock gets excited and jumps, then everyone remembers that drug development is hard and the stock gives back some gains. That's what happened with Medicus Pharma Ltd. (MDCX) on Thursday.
The company released topline data from its Phase 2 clinical trial for SKNJCT-003, which is evaluating a non-invasive treatment for basal cell carcinoma (BCC). BCC is the most common type of skin cancer—it's usually slow-growing and highly curable, but it still needs treatment. Medicus is trying to treat it with something called Doxorubicin Microneedle Array (D-MNA), which sounds exactly like what it is: tiny needles that deliver medication.
The results looked good: a 73% clinical clearance rate and a 40% histological clearance rate in the 200µg dose cohort. The study involved 90 patients with nodular BCC. The company called this "decision-grade evidence of clinical activity," which is biotech-speak for "good enough to keep going."
So why the stock volatility? Well, the market is trying to price in both the promise of the data and the reality of what comes next. The company aims to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses. They're hoping for an end-of-phase meeting with the FDA in the first half of 2026. That's still two years away—in biotech time, that's forever.
The technical picture tells its own story. The stock is currently trading 8.70% above its 20-day simple moving average (short-term strength) but 12.5% below its 100-day SMA (longer-term challenges). Over the past year, shares have decreased significantly and are positioned closer to their 52-week lows than highs. The RSI sits at 50.00—neutral territory, suggesting the stock isn't overbought or oversold. Meanwhile, the MACD is at 0.10, below its signal line at 0.15, indicating some bearish pressure. Traders are watching key resistance at $1.75 and support at $1.25.
In Thursday's premarket trading, Medicus Pharma shares were down 21.01% at $1.09. The stock is trading near its 52-week low of $0.91. So you have promising science, a long regulatory path ahead, and a stock that can't quite make up its mind what it wants to be when it grows up. Welcome to biotech investing.
